| |
Commercial
|
Medicare
|
|---|
| |
Pegfilgrastim Use
| |
Pegfilgrastim Use
|
|---|
|
No. (%) in Each Category
|
No
|
Yes
|
Unadjusted OR (95% CI)
|
No. (%) in Each Category
|
No
|
Yes
|
Unadjusted OR (95% CI)
|
|---|
|
Cycle 1
|
|
FN Events Prior to Cycle 1
|
|
No
|
50,778 (100%)
|
16,512 (33%)
|
34,266 (67%)
|
–
|
71,037 (100%)
|
20,195 (28%)
|
50,842 (72%)
|
–
|
|
Yes
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
|
Cycle 2
|
41,769
|
11,719 (28%)
|
30,050 (72%)
| |
59,412
|
15,193 (26%)
|
44,219 (74%)
| |
|
FN Events Prior to Cycle 2
|
|
No
|
40,123 (96%)
|
11,482 (29%)
|
28,641 (71%)
|
–
|
55,488 (93%)
|
14,483 (26%)
|
41,005 (74%)
|
–
|
|
Yes
|
1646 (4%)
|
237 (14%)
|
1409 (86%)
|
2.4 (2.1–2.7)
|
3924 (7%)
|
710 (18%)
|
3214 (82%)
|
1.6 (1.5–1.7)
|
|
Cycles ≥3
|
98,075
|
24,834 (25%)
|
73,241 (75%)
| |
141,495
|
43,012 (30%)
|
98,483 (70%)
| |
|
FN Events Prior to Cycle of Interest
|
|
No
|
91,744 (94%)
|
23,875 (26%)
|
67,869 (74%)
|
–
|
126,424 (89%)
|
39,360 (31%)
|
87,064 (69%)
|
–
|
|
Yes
|
6331 (6%)
|
959 (15%)
|
5372 (85%)
|
2.0 (1.8–2.1)
|
15,071 (11%)
|
3652 (24%)
|
11,419 (76%)
|
1.4 (1.4–1.5)
|
|
Last Cycle
|
34,860
|
10,188 (29%)
|
24,672 (71%)
| |
51,989
|
20,099 (39%)
|
31,890 (61%)
| |
|
FN Events Prior to Last Cycle
|
|
No
|
32,541 (93%)
|
9774 (30%)
|
22,767 (70%)
|
–
|
46,115 (89%)
|
18,215 (39%)
|
27,900 (61%)
|
–
|
|
Yes
|
2319 (7%)
|
414 (18%)
|
1905 (82%)
|
2.0 (1.8–2.2)
|
5874 (11%)
|
1884 (32%)
|
3990 (68%)
|
1.4 (1.3–1.5)
|
|
All Cycles
|
190,622
|
53,065 (28%)
|
137,557 (72%)
| |
271,944
|
78,400 (29%)
|
193,544 (71%)
| |
|
FN Events Prior to Cycle of Interest
|
|
No
|
182,645 (96%)
|
51,869 (28%)
|
130,776 (72%)
|
–
|
252,949 (93%)
|
74,038 (29%)
|
178,911 (71%)
|
–
|
|
Yes
|
7977 (4%)
|
1196 (15%)
|
6781 (85%)
|
2.2 (2.1–2.4)
|
18,995 (7%)
|
4362 (23%)
|
14,633 (77%)
|
1.4 (1.3–1.4)
|
- FN febrile neutropenia
- *Only consecutive qualifying cycles, beginning with cycle 1, were considered in this analysis (e.g., in identifying FN events [broad definition] in a prior cycle of the course of interest)
